Blueprint Medicines Corporation (LON: 0HOJ)
London
· Delayed Price · Currency is GBP · Price in USD
112.34
+3.04 (2.78%)
Jan 22, 2025, 6:59 PM BST
Blueprint Medicines Revenue
Blueprint Medicines had revenue of $128.18M USD in the quarter ending September 30, 2024, with 126.61% growth. This brings the company's revenue in the last twelve months to $434.42M, up 100.93% year-over-year. In the year 2023, Blueprint Medicines had annual revenue of $249.38M with 22.22% growth.
Revenue (ttm)
$434.42M
Revenue Growth
+100.93%
P/S Ratio
n/a
Revenue / Employee
$663.23K
Employees
655
Market Cap
5.73B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 249.38M | 45.34M | 22.22% |
Dec 31, 2022 | 204.04M | 23.96M | 13.30% |
Dec 31, 2021 | 180.08M | -613.66M | -77.31% |
Dec 31, 2020 | 793.74M | 727.22M | 1,093.37% |
Dec 31, 2019 | 66.51M | 21.99M | 49.39% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Blueprint Medicines News
- 9 days ago - Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor - GuruFocus
- 10 days ago - Blueprint Medicines Corp (BPMC) Unveils 2025 Growth Strategy and Promising Clinical Developments - GuruFocus
- 10 days ago - Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth - PRNewsWire
- 5 weeks ago - Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 6 weeks ago - Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting - PRNewsWire
- 2 months ago - Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs - Seeking Alpha
- 2 months ago - Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Benzinga
- 3 months ago - Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript - Seeking Alpha